Global Bispecific Antibody Is Expected To Surpass US$ 40 Billion By 2029 Says Kuick ResearchDelhi, Nov. 25, 2024 (GLOBE ...
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of ...
Medpage Today on MSN4d
FDA Approves Zanidatamab for Biliary Tract CancerPatients in the open-label phase II trial had progressed on at least one gemcitabine-containing regimen and received ...
The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...
US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...
The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...
Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...
Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback